BCR-ABL imatinib resistance-associated peptides and methods of use thereof

摘要

The present invention is directed to immunogenic peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a cancer associated with an activated kinase, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing cancer cells which are associated with an activated kinase.